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ABSTRACT
Background. The PROPKD score has been proposed to stratify
the risk of progression to end-stage renal disease in autosomal
dominant polycystic kidney disease (ADPKD) subjects. We
aimed to assess its prognostic value in a genotyped subgroup of
subjects from the Tolvaptan Phase 3 Efﬁcacy and Safety Study in
Autosomal Dominant Polycystic Kidney Disease (TEMPO3/4)
trial.
Methods. In the post hoc analysis, PKD1 and PKD2 were
screened in 770 subjects and the PROPKD score was calculated
in mutation-positive subjects (male: 1 point; hypertension
<35 years: 2 points; ﬁrst urologic event <35 years: 2 points;
nontruncating PKD1 mutation: 2 points; truncating PKD1
mutation: 4 points). Subjects were classiﬁed into low-risk (LR;
0–3 points), intermediate-risk (IR; 4–6 points) and high-risk
(HR; 7–9 points) groups.
Results. The PROPKD score was calculated in 749 subjects
(LR¼ 132, IR¼ 344 and HR¼ 273); age was inversely related
to risk (LR¼ 43.6 years, IR¼ 39.5 years, HR¼ 36.2 years;
P< 0.001). Subjects from the HR group had signiﬁcantly higher
height-adjusted total kidney volume (TKV) and rates of TKV
growth. While baseline renal function was similar across all risk
groups, the rate of estimated glomerular ﬁltration rate (eGFR)
decline signiﬁcantly increased from LR to HR in the placebo
group. Tolvaptan treatment effectiveness to reduce TKV growth
was similar in all three risk categories. While tolvaptan
signiﬁcantly slowed eGFR decline in the IR (tolvaptan¼2.34
versus placebo¼3.33mL/min/1.73m2/year; P¼ 0.008) and
HR groups (tolvaptan¼2.74 versus placebo¼3.94mL/
min/1.73 m2/year; P¼ 0.002), there was no difference in the LR
group (tolvaptan¼2.35 versus placebo¼2.50mL/min/1.73
m2/year; P¼ 0.72). Excluding the LR subjects from the analysis
improved the apparent treatment effect of tolvaptan on eGFR
decline.
Conclusion. This study conﬁrms the prognostic value of the
PROPKD score and suggests that it could reduce costs and
enhance endpoint sensitivity by enriching future study popula-
tions for rapidly progressing ADPKD subjects.
Keywords: autosomal dominant polycystic kidney disease,
genetics, PKD1, PKD2, TEMPO 3/4
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is
the fourth leading cause of end-stage renal disease (ESRD)
worldwide [1], with a prevalence of renal replacement
therapy (RRT) calculated at 91.1 per million in Europe [2].
The course of ADPKD varies considerably among individu-
als, with some reaching ESRD before 40 years of age and
others living a normal lifespan without requiring RRT. Two
principal genes, PKD1 and PKD2, are involved in 72–77%
VC The Author 2017. Published by Oxford University Press
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and 13–18% of cases, respectively [3–8]. A third gene,
GANAB, has recently been described, which causes milder
polycystic kidney disease but in some cases severe polycystic
liver disease [9]. Genetic variability strongly influences the
severity of ADPKD, with PKD1 truncating mutations typi-
cally associated with an earlier age at ESRD (median age
58 years) than PKD1 nontruncating mutations (67 years)
and PKD2mutations (79 years) [3].
Substantial progress in understanding the pathogenesis of
ADPKD has triggered the development of new therapeutic strat-
egies [10]. Tolvaptan, a vasopressin 2 receptor antagonist, was
demonstrated to slow the rate of total kidney volume (TKV)
growth and the rate of kidney function decline in the Tolvaptan
Efficacy and Safety in Autosomal Dominant Polycystic Kidney
Disease (TEMPO) trial [11]. A post hoc analysis suggested clini-
cally similar beneficial effects of tolvaptan in ADPKD across
chronic kidney disease (CKD) Stages 1–3, as defined by the
Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation [12].
Two major factors have made the design of clinical trials in
ADPKD particularly challenging. First, the significant variabil-
ity of renal disease severity complicates the evaluation of candi-
date drugs, as nonselected cohorts are highly heterogeneous.
Second, the loss of kidney function [evaluated by estimated glo-
merular filtration rate (eGFR)] usually happens gradually,
when irreversible structural damage has occurred and interven-
tion is unlikely to be successful. Consequently, classic clinical
endpoints such as doubling of serum creatinine or onset of
ESRD are difficult to study in a placebo-controlled trial of rea-
sonable length. Ideally, patients at risk of rapid progression
should be selected and treatment should be initiated early to
maximize the chance of detecting therapeutic effects in a limited
population size [13].
Several approaches have been developed to assess the
severity and the prognosis of ADPKD. Previous studies from
the Consortium for Radiologic Imaging Study of PKD (CRISP)
provided a strong rationale for the prognostic value of TKV,
including height adjusted (HtTKV), in ADPKD [14–19]. The
Mayo imaging classification (MIC) was developed to predict
the rate of decline of eGFR according to the HtTKV at a given
age [20]. The authors recommended enriching clinical trials
with patients who present with typical imaging presentations
and higher HtTKV/age, specifically imaging categories 1C–1E.
Aside from the imaging-based prognostic strategies, a different
approach was developed in the French cohort Genkyst, which
aims to include all the consenting ADPKD patients from the
western part of France, irrespective of their disease severity. The
Predicting Renal Outcome in Polycystic Kidney Disease
(PROPKD) score, based on clinical and genetic data, was shown
to stratify the risk of progression to ESRD [4]. The authors sug-
gested enriching clinical trials with subjects classified as high
risk by the PROPKD score.
In this post hoc analysis involving a subgroup of subjects
from the TEMPO 3/4 trial with genetic data available, we first
aimed to assess the prognostic value of the PROPKD score. Our
second objective was to investigate whether risk stratification
using the PROPKD score in the TEMPO 3/4 trial, by excluding
subjects from the low-risk group, where progression of TKV
and eGFR would be expected to be slowest, may have further
enriched the population for subjects with rapidly progressing
ADPKD enhancing discriminative ability.
MATERIALS AND METHODS
Study design
This is a post hoc exploratory analysis of TEMPO 3/4, a pro-
spective, randomized, double-blinded trial in 1445 ADPKD
adult patients (18–50 years) with an estimated creatinine clear-
ance (Cockroft and Gault) >60mL/min and a TKV >750mL/
min. The participants were randomized in a 2:1 ratio to receive
tolvaptan or placebo [11, 21].
Study participants
TEMPO 3/4 participants with available genetic analysis were
included in this study, namely subjects enrolled in the open-
label extension trial TEMPO 4/4 who consented to provide a
blood sample for DNA analysis [22]. The PROPKD score was
calculated in all the subjects in whom a mutation of PKD1 or
PKD2was identified (n¼ 749).
Molecular analysis of the PKD1 and PKD2 genes
The entire coding regions of the PKD1 and PKD2 genes and
their flanking intronic regions were screened by Sanger sequenc-
ing, followed if negative by the detection of gross rearrangements
using multiplex ligation-dependent probe amplification [23, 24].
Calculation of the PROPKD
The PROPKD score, ranging from 0 to 9 points, was calcu-
lated in the mutation-positive subjects as the sum of the follow-
ing factors: being a male: 1 point; hypertension onset before age
35 years: 2 points; first urologic event before age 35 years (includ-
ing cyst infection, gross hematuria and/or flank pain related to
cysts): 2 points; PKD2 mutation: 0 points; nontruncating muta-
tion of PKD1: 2 points; truncating mutation of PKD1: 4 points
(Supplementary data, Table S1). Subjects were classified into
low-risk (LR; 0–3 points), intermediate-risk (IR; 4–6 points) and
high-risk (HR; 7–9 points) groups (Supplementary data, Table
S1) [4]. For subjects <35 years of age who had not developed
hypertension and/or urological events, a score of 0 was allocated
to these clinical variables and the score calculated as the sum of
the remaining factors.
Outcome measure
Two endpoints of the TEMPO 3/4 trial were considered in
this analysis: the primary outcome measure, which was the
annual rate of change in TKV over time, and the secondary out-
comemeasure, the rate of kidney function decline.
Statistical analyses
Annualized TKV growth rate was calculated in each risk
subgroup by regressing logarithm-transformed kidney volume
data against time and then displaying regression slope exponen-
tials. All eGFR values presented were calculated using the CKD-
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EPI formula [25]. The rate of eGFR decline was obtained in
each risk subgroup by regressing eGFR from steady-state after
baseline (i.e. Week 3 and beyond) against time by subject.
Treatment effects for both endpoints corresponded to the dif-
ference between the slopes of tolvaptan and placebo.
RESULTS
Description of the study population and comparison of
risk groups defined by the PROPKD score at baseline
Molecular analysis of PKD1 and PKD2 was conducted in
770 subjects. The mutation detection rate was high, with muta-
tions identified in 749 subjects (97.3%; 583 different mutations),
of whom 61.3% had a truncating PKD1 mutation, 26.3% had a
nontruncating PKD1 mutation and 12.4% had a PKD2 muta-
tion. A majority of the mutations identified were private, the
two most frequent variants were the missense c.8311G>A
(p.Glu2771Lys) and the frameshifting deletion c.5014_
5015delAG (p.Arg1672fs97X), each identified in 2% of the sub-
jects (n¼ 15). Baseline and demographic characteristics in these
749 tolvaptan- and placebo-treated subjects were well-balanced
overall and similar to baseline characteristics in the TEMPO 3/4
trial (Supplementary data, Table S2). After calculation of the
PROPKD score in the 749mutation-positive patients, most sub-
jects were categorized to the more severe risk groups [n¼ 132
(17.6%) in LR, 344 (45.9%) in IR and 273 (36.5%) in HR], with
the mean age inversely related to risk (LR¼ 43.6 years,
IR¼ 39.5 years, HR¼ 36.3 years; P< 0.001) (Table 1).
At baseline, while HtTKV was significantly higher in the HR
group than in the IR and LR groups (respective median values
of 947, 784 and 785mL/m; P< 0.005), eGFR was similar in the
three groups (Table 1, panel A).
Patients with no mutation detected
While age and eGFR at baseline were similar in the 21
patients with no mutation detected (NMD) and the 749
mutation-positive subjects, median baseline TKV (1167mL)
and HtTKV (648mL/m) were lower (P-values 0.015 and 0.018,
respectively) and these subjects were more frequently classified
at lower risk by the MIC (Class 2 or 1B) (38.1% versus 10.2%;
P¼ 0.009).
Rate of TKV growth and PROPKD risk categories
Rate of TKV growth was significantly higher in subjects clas-
sified in the HR group than those in the IR and LR groups for
both treatment arms. Indeed, in placebo-treated subjects, the
rate of TKV growth in the HR group was 32–43% higher than
in the LR and IR groups, whereas in the tolvaptan-treated sub-
jects, TKV growth in the HR group was 48–80% higher than in
the LR and IR groups (Table 2, panel A). In the LR group, TKV
at baseline was significantly higher in the tolvaptan- versus
placebo-treated subjects (Table 1, panel B). However, TKV
growth was significantly lower in tolvaptan- versus placebo-
treated subjects in each of the risk groups. Treatment effect was
similar in the three risk groups (Table 2, panel A).
Rate of eGFR decline and PROPKD risk categories
In the placebo-treated subjects, the eGFR decline was greater
from the HR to the LR groups. While tolvaptan significantly
reduced the rate of renal function decline in the IR and HR
groups, with relative treatment effects of 30.3% and 30.6%, there
was no significant difference between the tolvaptan- and
placebo-treated subjects in the LR group (Table 2, panel A). In
the latter group, however, the eGFR at baseline was significantly
higher in the placebo-treated group (Table 1, panel B).
Effect of the exclusion of subjects from the LR group on
the outcome measures
We investigated the effect of excluding subjects from the LR
group [n¼ 132 (17.6%)]. While this exclusion did not change
the tolvaptan-mediated decrease in TKV growth rate (Figure
1A), there was a nonsignificant trend of increased treatment
effect on the rate of eGFR decline (treatment effect 30.6% after
exclusion of LR versus 27.1%). In the three combined groups,
tolvaptan reduced the rate of eGFR decline from 3.40 to
2.48mL/min/1.73 m2/year (P¼ 0.0001). Excluding subjects in
the LR group from the analysis increased this difference (3.62
to2.51mL/min/1.73 m2/year; P< 0.0001) (Figure 1B).
Stability of PROPKD risk groups in subjects <35 years
of age during the trial follow-up
The clinical variables included in the PROPKD score, i.e.
hypertension and urological events, are set as binary variables
occurring before 35 years (2 points) or not (0 points). Among
the 749 mutation-positive subjects, 168 were <35 years of age,
almost exclusively in the more severe groups (7 in LR, 61 in IR,
100 in HR). Fourteen of these subjects changed risk category
after 3 years of follow-up: 3 from LR to IR and 11 from IR to
HR (Figure 2).
Combination of the MIC and PROPKD approaches
To investigate whether the PROPKD score and the MIC
could be used as complementary enrichment strategies, we
studied the distribution of LR, IR and HR subjects in the differ-
ent classes of theMIC. As expected, HR subjects were more rep-
resented in the more severe classes (1C, 1D and 1E; Table 1,
panel A and Figure 3). While 75.7% of subjects were defined at
higher risk of significant progression by both methods (Group
1, i.e. IR and HR by the PROPKD and MIC groups 1C, 1D and
1E), only 3.6% were defined at low risk of progression by both
methods (Group 2), 14.1% were considered at higher risk only
by the MIC (Group 3) and 6.6% only by the PROPKD score
(Group 4). Consistent with the entry criteria of the TEMPO
trial, a majority of the subjects classified at lower risk by each
method were >35 years of age (96% for the MIC and 94% for
the PROPKD). Inversely, subjects from Group 1 had similar
baseline kidney function but were significantly younger than
patients fromGroup 3 and Group 4 [mean age 37 versus 43 and
43 years, respectively (P< 0.001)]. The proportion of subjects
from MIC Class 1C was significantly higher in the discordant
Group 3 than in the concordant Group 1 (59% versus 39.3%;
P< 0.001). Similarly, the proportion of subjects from the
PROPKD IR group was higher in the discordant Group 4 than
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in the concordant Group 1 (85.7% versus 40%; P< 0.001). This
suggests an overall milder disease in these two discordant sub-
groups. The most frequent missense variant, p.Glu2771Lys, was
more frequently identified in the discordant Group 3 than in
the rest of the cohort (5.7% versus 1.4%; P¼ 0.004).
To evaluate whether the PROPKD further improved the
imaging stratification in Classes 1C, 1D and 1E, we excluded
subjects classified as Class 2 (n¼ 18) and 1B (n¼ 58). In sub-
jects from Classes 1C, 1D and 1E, while tolvaptan reduced TKV
growth in each of the three PROPKD risk groups, it was associ-
ated with significantly slower renal function decline in the IR
and HR groups, but not in the LR group (Table 2, panel B).
DISCUSSION
Designing optimal clinical trials in ADPKD is a difficult task
given the lifelong progression of the disease and the high varia-
bility of its severity. Inclusion criteria in the TEMPO trial com-
bined volume and age thresholds in individuals with preserved
kidney function, thus enriching for patients with rapidly
progressive ADPKD. Reflecting this enrichment, when com-
pared with the Genkyst cohort, PKD1 truncating mutations
were more frequent in TEMPO patients (61.3% versus 53%)
and PKD2mutations less frequent (12.4% versus 20.2%).
The PROPKD score was developed in a population-based
cohort representative of the wide spectrum of disease severity in
adult ADPKD. Herein, we confirm the prognostic value of the
PROPKD score in a genotyped subgroup of subjects from the
TEMPO trial. Indeed, subjects from the HR group, although
younger, had higher HtTKVs at baseline and higher rates of
TKV growth. While subjects from the three risks groups had
similar average eGFR at baseline, we observed increasingly
steeper rates of eGFR decline from the LR to the HR group.
This study provides strong validation of the prognostic value of
the PROPKD score for two reasons. First, it demonstrates that
the PROPKD score stratifies the risk for disease progression
even in ADPKD patients selected to have rapidly progressive
disease. Second, although the PROPKD score was developed to
predict age at ESRD, we show here that it also predicts rates of
eGFR decline and TKV growth.
Table 1. Baseline characteristics
(A) Comparison of the baseline characteristics in the three PROPKD risk groups
LR PROPKD 1–3 IR PROPKD
4–6
HR PROPKD
7–9
P-values
(n ¼ 132) (n ¼ 344) (n ¼ 273) LR to IR IR to HR LR to HR
Age (years), mean (SD) 43.6 (5.3) 39.5 (6.6) 36.3 (6.8) <0.0001 <0.0001 <0.0001
Caucasian, n (%) 124 (93.9) 339 (98.5) 259 (94.9) 0.01 0.7 0.003
Male, n (%) 80 (60.6) 101 (29.3) 209 (76.6) <0.0001 <0.0001 0.002
Age at diagnosis of ADPKD (years), mean (SD) 35.4 (8.6) 26.7 (8.9) 23.6 (7.7) <0.0001 <0.0001 <0.0001
HTN, n (%) 108 (81.8%) 277 (80.5%) 252 (92.3%) 0.80 <0.0001 0.003
Age at diagnosis of HTN, (years), mean (SD) 38.3 (5.77) 33.1 (7.9) 26.5 (6.5) <0.0001 <0.0001 <0.0001
Median TKV (mL) (IQR) 1367 (838–1896) 1338 (916–1759) 1682 (1181–2182) 0.15 <0.0001 0.002
Median HtTKV (mL/m), (IQR) 785 (492–1077) 784 (545–1022) 947 (663–1231) 0.28 <0.0001 0.005
eGFRCKD-EPI (mL/min/1.73 m
2, mean (SD) 84.8 (21.1) 83.4 (20.9) 82.3 (23.1) 0.56 0.49 0.32
Genotype, n (%)
PKD1 truncating 0 (0.0) 219 (63.7) 240 (87.9) <0.0001 <0.0001 <0.0001
PKD1 nontruncating 53 (40.2) 111 (32.2) 33 (12.1) 0.11 <0.0001 <0.0001
PKD2 79 (59.8) 14 (4.1) 0 (0.0) <0.0001 0.304 <0.0001
Mayo imaging class, n (%)
Class 2 10 (7.6) 7 (2) 1 (0.4) 0.097 0.0831 <0.0001
Class 1B 17 (12.9) 35 (10.2) 6 (2.2) 0.41 <0.0001 <0.0001
Class 1C 62 (47) 151 (43.9) 70 (25.6) 0.61 0.0119 0.003
Class 1D 36 (27.2) 113 (32.8) 117 (42.9) 0.27 <0.0001 <0.0001
Class 1E 7 (5.3) 36 (10.5) 76 (27.8) 0.11 <0.0001 <0.0001
Missing 0 2 (0.6) 3 (1.1)
(B) Comparison of the baseline characteristics in the tolvaptan-(T) and placebo (P)-treated patients within each PROPKD risk group
LR PROPKD 1–3 IR PROPKD 4–6 HR PROPKD 7–9
T (n ¼ 79) P (n ¼ 53) T (n ¼ 226) P (n ¼ 118) T (n ¼ 167) P (n ¼ 106)
Age (years), mean (SD) 43.7 (5.0) 43.5 (5.8) 39.2 (6.7) 40.2 (6.5) 36.3 (6.4) 36.1 (7.3)
Caucasian, n (%) 75 (94.9) 49 (92.5) 222 (98.2) 117(99.2) 157 (94) 102 (96.2)
Male, n (%) 50 (63.3) 30 (56.6) 74 (32.7) 27 (22.9) 135* (80.8) 74* (69.8)
TKV (mL), median (IQR) 1574* 1241* 1330 1352 1699 1677
(1009–2138) (943–1538) (905–1754) (950–1754) (1163–2235) (1216–2138)
HtTKV (mL/m), median (IQR) 917* 705* 756 793 952 939
(596–1238) (538–871) (520–991) (553–1032) (666–1238) (663–1215)
eGFRCKD-EPI, mean mL/min/1.73 m
2 (SD) 81.1* (18.5) 90.3* (23.6) 83.7 (20.7) 82.9 (21.4) 82.0 (22.5) 82.8 (24.1)
HTN, hypertension; IQR, interquartile range.
*P-value between T and P< 0.05.
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Our second objective was to investigate whether excluding
subjects from the LR group defined by the PROPKD score may
have enhanced the discriminative ability of the TEMPO trial.
As a result of the TEMPO entry criteria, a higher proportion of
subjects was classified in the HR (36.5%) and IR groups (45.9%)
when compared with the Genkyst cohort, where the HR and IR
groups represented 14% and 46.7% of the subjects, respectively
[4]. In this post hoc analysis, exclusion of the 132 LR group sub-
jects (17.6%) slightly maximized the difference in the rate of
eGFR decline between the tolvaptan- and the placebo-treated
subjects. The treatment effect on the rate of TKV growth was
similar in the three risk groups.
This analysis demonstrates that the PROPKD score can
be used to enrich clinical trial cohorts for rapidly progressive
patients, and complement enrichment from TKV criteria, to
increase the chances of observing significant differences in
the rate of kidney function decline. Such strategies in future
trials may allow cost reductions by decreasing the number of
subjects to recruit while maximizing the chance of positive
results. While the high cost of a comprehensive analysis of
PKD genes has long been a disincentive, the current wide-
spread use of next-generation sequencing allows significant
cost reductions and is likely to facilitate access to genetic
testing [26–30].
Two recent studies evaluating an enrichment strategy using
the MIC have been published [31, 32]. The first post hoc analy-
sis was conducted in early disease in the HALT-PKD study, a
randomized controlled trial that studied the effect of rigorous
versus standard blood pressure control on rates of TKV
increase and eGFR decline in ADPKD subjects ages 15–49 years
with preserved renal function (eGFR> 60mL/min/1.73 m2) at
inclusion [33]. Treatment was more beneficial in subjects from
Classes 1D and 1E, both in terms of TKV increase and eGFR
decrease. This cohort of subjects was more heterogeneous in
terms of disease severity than in the TEMPO 3/4 trial. Analysis
of the PROPKD score performance in that population would be
interesting, but age at the first urological event was not system-
atically collected. The second post hoc analysis was conducted
in the TEMPO trial [32]. Exclusion of Class 2A and 1B subjects
resulted in a slightly higher treatment effect on TKV and eGFR
slopes, although nonsignificant. Interestingly in our study, 105
subjects from MICs 1C–1E were categorized in the PROPKD
LR group. Subjects in this subgroup were significantly older and
more frequently classified as MIC 1C, suggesting an overall
milder disease in this discordant subgroup. In subgroup analy-
sis including only the 668 subjects from MICs 1C–1E, the rate
of eGFR decline was lower in the LR than in the IR and HR
groups. And while treatment was associated with a slower renal
function decline in the HR and IR groups, there was no differ-
ence from placebo in the LR group. This suggests that combin-
ing imaging, genetics and clinical criteria in a single scoring
system may be of interest to develop future prognostic tools in
ADPKD. Such an approach will allow evaluation of the relative
contributions of the different predictors and provide accurate
Table 2. Rate of change in TKV and eGFR by PROPKD risk categories
(A) Analysis in the 749 individuals included in the post hoc analysis
Variable LR IR HR
T P T P T P
(n ¼ 79) (n ¼ 53) (n ¼ 226) (n ¼ 118) (n ¼ 167) (n ¼ 106)
Rate of TKV growth (%/year) 2.80 5.11 2.30 4.72 4.15 6.75
P-value 0.0022 <0.0001 <0.0001
Relative treatment effect (%) 45.8 51.8 38.2
T P T P T P
(n ¼ 79) (n ¼ 52) (n ¼ 214) (n ¼ 115) (n ¼ 159) (n ¼ 103)
Rate of eGFRCKD-EPI decline (mL/min/1.73 m
2) 2.35 2.50 2.34 3.33 2.74 3.94
P-value 0.72 0.008 0.002
Relative treatment effect (%) 6.9 30.3 30.6
(B) Subgroup analysis in patients from MICs C, D and E (n¼ 668)
Variable LR IR HR
T P T P T P
(n ¼ 65) (n ¼ 40) (n ¼ 196) (n ¼ 104) (n ¼ 160) (n ¼ 103)
Rate of TKV growth (%/year) 2.71 5.36 2.47 5.08 4.27 6.9
P-value 0.0010 <0.0001 <0.0001
Relative treatment effect (%) 50.4 52.2 38.1
T P T P T P
(n ¼ 65) (n ¼ 39) (n ¼ 186) (n ¼ 101) (n ¼ 152) (n ¼ 100)
Rate of eGFRCKD-EPI decline (mL/min/1.73 m
2) 2.55 2.58 2.47 3.53 2.74 4.11
P-value 0.91 0.009 0.0003
Relative treatment effect (%) 2.3 30.5 33.7
P, placebo; T, tolvaptan.
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prognostic information earlier: before the occurrence of signifi-
cant volume enlargement and/or hypertension or a urological
event. Meanwhile, the use of both tools seems particularly inter-
esting in patients at intermediate risk, for instance using
PROPKD to reclassify subjects from MIC 1C and MIC to
reclassify subjects from the PROPKD IR group, depending on
which prognosis tool was used first.
Tolvaptan is now available in Canada, Japan, Europe, South
Korea and Switzerland and a position statement for the use of
tolvaptan has recently been issued by a European group of
experts [34]. One of the objectives of this group was to define
the definition of ‘evidence of rapid disease progression’. Besides
historical kidney growth and eGFR decline, demonstrated by
sequential imaging or creatinine measurements, the authors
suggested that subjects from MICs 1C–1E or from the
PROPKD HR group were likely to have rapid progression.
Taking into account the results of the present study, subjects
from the PROPKD IR group should also be considered at risk
for rapid progression, although wemust keep inmind that these
subjects met the inclusion criteria for the TEMPO trial and so
potentially had more rapid progression than nonpreselected IR
group subjects.
This study has some limitations. First, this is a post hoc anal-
ysis, which was run in a subgroup of the TEMPO trial, and a
sample for genetic analysis was collected on only 53% of sub-
jects. As a consequence, the LR group was quite small and base-
line characteristics between placebo- and tolvaptan-treated
patients differed significantly in this subgroup. Reassuringly,
baseline characteristics in the genotyped subgroup were similar
to the full TEMPO 3/4 cohort [11]. Second, while disease
severity is overall milder in patients with nontruncating
variants, a handful of missense variants has been shown in vitro
to be fully penetrant, including p.Glu2771Lys, which disrupts
cleavage of polycystin 1 at the G-protein coupled receptor
proteolytic site [35, 36], and was more frequent in subjects
considered at higher risk only by the MIC. Attributing
four points (truncating mutation) rather than two points
(nontruncating mutation) for the genetic component of the
FIGURE 2: Classiﬁcation remains stable in most patients over time.
Flowchart representing the classiﬁcation of the 749 subjects in the
three PROPKD risk groups at baseline and after 3 years of follow-up.
Fourteen of these subjects changed risk category after 3 years of fol-
low-up: 3 from LR to IR and 11 from IR to HR as a consequence of a
diagnosis of hypertension in 10 subjects and the occurrence of a ﬁrst
urological event in 6 subjects.
FIGURE 3: Distribution of LR, IR and HR groups in each category
of the MIC model.
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FIGURE 1: (A) Rate of TKV growth in the LR group, in the com-
bined HR and IR group and in the three combined groups. (B) Rate
of eGFR decline in the LR group, in the combined HR and IR group
and in the three combined groups. Error bars represent the standard
error of the mean.
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PROPKD score in the 2% of ADPKD patients harboring
this mutation would improve their prognostic assessment. In
the future, the development of functional assays will allow
more refined variant classification. Moreover, in 21 patients
no mutation of PKD1 or PKD2 was identified and thus the
PROPKD score could not been calculated. Aside from missed
mutations in the complex PKD1 gene, or in the intronic
portions of both genes, missense variants of unknown signif-
icance or mosaic cases may explain some of these genetically
unresolved cases, which is suggested by the higher propor-
tion of subjects from MIC 2, i.e. with segmental, asymmetric
or lopsided imaging presentation. Mutations in GANAB are
unlikely to be involved here, as none of the 20 GANAB
patients reported so far would have met the age and TKV
inclusion criteria of the TEMPO 3/4 trial [9]. Nevertheless,
the mutation detection rate was particularly high in this
cohort, with only 2.7% of the subjects having NMD, com-
pared with 7–10% in other recent ADPKD cohorts [3, 4, 7,
24]. A potential explanation is that subjects with NMD tend
to have milder disease [7] and were hence less likely to be
included in the TEMPO trial. Last, due to the scoring criteria,
the PROPKD score can increase in subjects <35 years of age
if they develop hypertension or experience a first urological
event. Therefore, excluding young LR group subjects from
studies and treatment has the risk of removing a few subjects
with rapidly progressive disease. The follow-up analysis in
the TEMPO trial timeframe is reassuring, as only three sub-
jects moved from the LR to the IR group.
In conclusion, the PROPKD score is an efficient strategy to
enrich future randomized control trials cohorts for rapidly pro-
gressive patients. Ultimately, the combination of imaging and
genetic-based approaches will likely enhance our capacity to
predict renal outcomes and tailor therapeutic approaches to
individual ADPKD patients.
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